Global Cytotoxic Drug

Cytotoxic Drug Comprehensive Study by Application (Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other), Dosage (Injection, Solid Oral, Others) Players and Region - Global Market Outlook to 2028

Cytotoxic Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Cytotoxic drugs also known as cytotoxic chemotherapy are drugs used to destroy cancer cells. Cytotoxic drugs prevent cell division and in this way cause cancer cells to die. These drugs are transported in the bloodstream throughout the body. Furthermore, the cytotoxic drugs can be used to destroy tumors, boost the outcomes of surgery or radiotherapy, reduce metastases and alleviate cancer symptoms. It can be effective outside the primary tumor and also destroy small tumors that have not been detected in tests. Cytotoxic drugs affect all dividing cells, with those of healthy tissue. But because cancer cells often divide markedly faster than normal cells, they are particularly sensitive to cytotoxic drugs. The effects on normal cells are less and healthy cells are also recover faster.This growth is primarily driven by Increase in Incidence of Cancer Across the Globe .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Roche Holding AG (Switzerland), Eli Lilly (United States), Celgene (United States), Sanofi (France), Eisai (Japan), Jazz Pharmaceuticals (Ireland), Sumitomo Dainippon Pharma (Japan), Merck & Co. (United States), Novartis (Switzerland) and AstraZeneca (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:

In March 2022, GlaxoSmithKline and Merck KGaA announced a collaboration to develop new cancer treatments. The two companies will work together to develop new combination therapies and explore ways to use artificial intelligence to personalize cancer treatment.The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period.

Regulatory Insights:
Cytotoxic test kits promoted or offered for the diagnosis of allergic diseases would be adulterated and misbranded unless approval has been granted by FDA.

Influencing Trend:
Technological Developments in Cytotoxic Drug Treatment

Market Growth Drivers:
Increase in Incidence of Cancer Across the Globe, Growth in Global Geriatric Population and Rise in Government Expenditures on Healthcare

Challenges:
The Role of Cytotoxic Drugs in Cancer Therapy Has Decreased Slightly With the Development of Drug Therapy

Restraints:
Adverse Side Effects of Cytotoxic Drugs

Opportunities:
Untapped Market of Emerging Economies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Cytotoxic Drug Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Cytotoxic Drug Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Cytotoxic Drug players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Cytotoxic Drug Study Sheds Light on
— The Cytotoxic Drug Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cytotoxic Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cytotoxic Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Breast Cancer
  • Blood Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Other
By Dosage
  • Injection
  • Solid Oral
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Incidence of Cancer Across the Globe
      • 3.2.2. Growth in Global Geriatric Population
      • 3.2.3. Rise in Government Expenditures on Healthcare
    • 3.3. Market Challenges
      • 3.3.1. The Role of Cytotoxic Drugs in Cancer Therapy Has Decreased Slightly With the Development of Drug Therapy
    • 3.4. Market Trends
      • 3.4.1. Technological Developments in Cytotoxic Drug Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cytotoxic Drug, by Application, Dosage and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cytotoxic Drug (Value)
      • 5.2.1. Global Cytotoxic Drug by: Application (Value)
        • 5.2.1.1. Breast Cancer
        • 5.2.1.2. Blood Cancer
        • 5.2.1.3. Prostate Cancer
        • 5.2.1.4. Respiratory/Lung Cancer
        • 5.2.1.5. Other
      • 5.2.2. Global Cytotoxic Drug by: Dosage (Value)
        • 5.2.2.1. Injection
        • 5.2.2.2. Solid Oral
        • 5.2.2.3. Others
      • 5.2.3. Global Cytotoxic Drug Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Cytotoxic Drug (Price)
  • 6. Cytotoxic Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eisai (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Jazz Pharmaceuticals (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sumitomo Dainippon Pharma (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cytotoxic Drug Sale, by Application, Dosage and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cytotoxic Drug (Value)
      • 7.2.1. Global Cytotoxic Drug by: Application (Value)
        • 7.2.1.1. Breast Cancer
        • 7.2.1.2. Blood Cancer
        • 7.2.1.3. Prostate Cancer
        • 7.2.1.4. Respiratory/Lung Cancer
        • 7.2.1.5. Other
      • 7.2.2. Global Cytotoxic Drug by: Dosage (Value)
        • 7.2.2.1. Injection
        • 7.2.2.2. Solid Oral
        • 7.2.2.3. Others
      • 7.2.3. Global Cytotoxic Drug Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Cytotoxic Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cytotoxic Drug: by Application(USD Million)
  • Table 2. Cytotoxic Drug Breast Cancer , by Region USD Million (2017-2022)
  • Table 3. Cytotoxic Drug Blood Cancer , by Region USD Million (2017-2022)
  • Table 4. Cytotoxic Drug Prostate Cancer , by Region USD Million (2017-2022)
  • Table 5. Cytotoxic Drug Respiratory/Lung Cancer , by Region USD Million (2017-2022)
  • Table 6. Cytotoxic Drug Other , by Region USD Million (2017-2022)
  • Table 7. Cytotoxic Drug: by Dosage(USD Million)
  • Table 8. Cytotoxic Drug Injection , by Region USD Million (2017-2022)
  • Table 9. Cytotoxic Drug Solid Oral , by Region USD Million (2017-2022)
  • Table 10. Cytotoxic Drug Others , by Region USD Million (2017-2022)
  • Table 11. South America Cytotoxic Drug, by Country USD Million (2017-2022)
  • Table 12. South America Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 13. South America Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 14. Brazil Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 15. Brazil Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 16. Argentina Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 17. Argentina Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 18. Rest of South America Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 19. Rest of South America Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 20. Asia Pacific Cytotoxic Drug, by Country USD Million (2017-2022)
  • Table 21. Asia Pacific Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 22. Asia Pacific Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 23. China Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 24. China Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 25. Japan Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 26. Japan Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 27. India Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 28. India Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 29. South Korea Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 30. South Korea Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 31. Taiwan Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 32. Taiwan Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 33. Australia Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 34. Australia Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 36. Rest of Asia-Pacific Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 37. Europe Cytotoxic Drug, by Country USD Million (2017-2022)
  • Table 38. Europe Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 39. Europe Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 40. Germany Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 41. Germany Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 42. France Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 43. France Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 44. Italy Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 45. Italy Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 46. United Kingdom Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 47. United Kingdom Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 48. Netherlands Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 49. Netherlands Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 50. Rest of Europe Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 51. Rest of Europe Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 52. MEA Cytotoxic Drug, by Country USD Million (2017-2022)
  • Table 53. MEA Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 54. MEA Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 55. Middle East Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 56. Middle East Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 57. Africa Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 58. Africa Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 59. North America Cytotoxic Drug, by Country USD Million (2017-2022)
  • Table 60. North America Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 61. North America Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 62. United States Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 63. United States Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 64. Canada Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 65. Canada Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 66. Mexico Cytotoxic Drug, by Application USD Million (2017-2022)
  • Table 67. Mexico Cytotoxic Drug, by Dosage USD Million (2017-2022)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Cytotoxic Drug: by Application(USD Million)
  • Table 79. Cytotoxic Drug Breast Cancer , by Region USD Million (2023-2028)
  • Table 80. Cytotoxic Drug Blood Cancer , by Region USD Million (2023-2028)
  • Table 81. Cytotoxic Drug Prostate Cancer , by Region USD Million (2023-2028)
  • Table 82. Cytotoxic Drug Respiratory/Lung Cancer , by Region USD Million (2023-2028)
  • Table 83. Cytotoxic Drug Other , by Region USD Million (2023-2028)
  • Table 84. Cytotoxic Drug: by Dosage(USD Million)
  • Table 85. Cytotoxic Drug Injection , by Region USD Million (2023-2028)
  • Table 86. Cytotoxic Drug Solid Oral , by Region USD Million (2023-2028)
  • Table 87. Cytotoxic Drug Others , by Region USD Million (2023-2028)
  • Table 88. South America Cytotoxic Drug, by Country USD Million (2023-2028)
  • Table 89. South America Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 90. South America Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 91. Brazil Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 92. Brazil Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 93. Argentina Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 94. Argentina Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 95. Rest of South America Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 96. Rest of South America Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 97. Asia Pacific Cytotoxic Drug, by Country USD Million (2023-2028)
  • Table 98. Asia Pacific Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 99. Asia Pacific Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 100. China Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 101. China Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 102. Japan Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 103. Japan Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 104. India Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 105. India Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 106. South Korea Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 107. South Korea Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 108. Taiwan Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 109. Taiwan Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 110. Australia Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 111. Australia Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 112. Rest of Asia-Pacific Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 113. Rest of Asia-Pacific Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 114. Europe Cytotoxic Drug, by Country USD Million (2023-2028)
  • Table 115. Europe Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 116. Europe Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 117. Germany Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 118. Germany Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 119. France Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 120. France Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 121. Italy Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 122. Italy Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 123. United Kingdom Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 124. United Kingdom Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 125. Netherlands Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 126. Netherlands Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 127. Rest of Europe Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 128. Rest of Europe Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 129. MEA Cytotoxic Drug, by Country USD Million (2023-2028)
  • Table 130. MEA Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 131. MEA Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 132. Middle East Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 133. Middle East Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 134. Africa Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 135. Africa Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 136. North America Cytotoxic Drug, by Country USD Million (2023-2028)
  • Table 137. North America Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 138. North America Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 139. United States Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 140. United States Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 141. Canada Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 142. Canada Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 143. Mexico Cytotoxic Drug, by Application USD Million (2023-2028)
  • Table 144. Mexico Cytotoxic Drug, by Dosage USD Million (2023-2028)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cytotoxic Drug: by Application USD Million (2017-2022)
  • Figure 5. Global Cytotoxic Drug: by Dosage USD Million (2017-2022)
  • Figure 6. South America Cytotoxic Drug Share (%), by Country
  • Figure 7. Asia Pacific Cytotoxic Drug Share (%), by Country
  • Figure 8. Europe Cytotoxic Drug Share (%), by Country
  • Figure 9. MEA Cytotoxic Drug Share (%), by Country
  • Figure 10. North America Cytotoxic Drug Share (%), by Country
  • Figure 11. Global Cytotoxic Drug share by Players 2022 (%)
  • Figure 12. Global Cytotoxic Drug share by Players (Top 3) 2022(%)
  • Figure 13. Global Cytotoxic Drug share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 17. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lilly (United States) Revenue: by Geography 2022
  • Figure 19. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 20. Celgene (United States) Revenue: by Geography 2022
  • Figure 21. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi (France) Revenue: by Geography 2022
  • Figure 23. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Eisai (Japan) Revenue: by Geography 2022
  • Figure 25. Jazz Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Jazz Pharmaceuticals (Ireland) Revenue: by Geography 2022
  • Figure 27. Sumitomo Dainippon Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Sumitomo Dainippon Pharma (Japan) Revenue: by Geography 2022
  • Figure 29. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 33. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Global Cytotoxic Drug: by Application USD Million (2023-2028)
  • Figure 36. Global Cytotoxic Drug: by Dosage USD Million (2023-2028)
  • Figure 37. South America Cytotoxic Drug Share (%), by Country
  • Figure 38. Asia Pacific Cytotoxic Drug Share (%), by Country
  • Figure 39. Europe Cytotoxic Drug Share (%), by Country
  • Figure 40. MEA Cytotoxic Drug Share (%), by Country
  • Figure 41. North America Cytotoxic Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Holding AG (Switzerland)
  • Eli Lilly (United States)
  • Celgene (United States)
  • Sanofi (France)
  • Eisai (Japan)
  • Jazz Pharmaceuticals (Ireland)
  • Sumitomo Dainippon Pharma (Japan)
  • Merck & Co. (United States)
  • Novartis (Switzerland)
  • AstraZeneca (United Kingdom)
Additional players considered in the study are as follows:
Spectrum Pharmaceuticals (United States) , Seattle Genetics (United States) , Hansoh Pharma (China) , Takeda Pharmaceutical Company (Japan)
Select User Access Type

Key Highlights of Report


Nov 2023 248 Pages 70 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cytotoxic Drug Quantitative research analysis
Global Cytotoxic Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Cytotoxic Drug Market are Roche Holding AG (Switzerland), Eli Lilly (United States), Celgene (United States), Sanofi (France), Eisai (Japan), Jazz Pharmaceuticals (Ireland), Sumitomo Dainippon Pharma (Japan), Merck & Co. (United States), Novartis (Switzerland) and AstraZeneca (United Kingdom) etc.
Breast Cancer segment in Global market to hold robust market share owing to "Increase in Incidence of Cancer Across the Globe ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Cytotoxic Drug market throughout the forecasted period.

Know More About Global Cytotoxic Drug Report?

Have a Query? Click Here

Other Related Reports

Pharma & Cosmetics Comprehensive Study by Distribution Channel (Supermarket, Onlien Stores, Cosmetics Stores, Drug Stores), Cosmetics (Skincare, Haircare, Oral Care, Others), Pharmaceutical (Tablets,...
$ 3450
Contrast Agents Comprehensive Study by Type (Iodine-based, Barium-Sulfate, Gadolinium), Application (Interventional Radiology, Interventional Cardiology), Route of Administration (Intravenously/intra...
$ 3750
Skin Adhesives Comprehensive Study by Application (Ophthalmic Surgery, ENT Surgery, Dental Surgery, General Surgery, Plastic Surgery, Gynaecology, Gastroenterology, Orthopaedic, Surgical oncology, Ot...
$ 3650
Left Ventricular Dysfunction Drug Comprehensive Study by Type (BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others), Application (Hospital, Clinic, Others), Drug Type (Prescript...
$ 3450
Animal Parasiticides - Comprehensive Study by Type (Endoparasiticides (Oral, Injectables), Ectoparasiticides (Sprays, Pour On, Spot On), Endectocides), Application (Agriculture, Horticulture), Form (...
$ 3350
Guillain-Barre Syndrome Drugs Comprehensive Study by Type (Coversin, Immune Globulin, Others), Application (Clinic, Hospital, Others), Forms (Tablets, Injection), Distribution Channel (Hospital Pharm...
$ 3350